ARTICLE | Deals
Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
November 26, 2024 12:24 AM UTC
With a pivotal readout looming in early 2025, Kura has tapped Kyowa Kirin as a global partner for its menin inhibitor for acute myelogenous leukemia, adding $330 million up front to its balance sheet with the potential for more near-term milestones to follow.
Kura Oncology Inc. (NASDAQ:KURA) expects data within the next several weeks from the registrational Phase II portion of its KOMET-1 trial of zeftomenib, evaluating the candidate in patients with relapsed or refractory NPM1-mutant AML. Ahead of that readout, Kyowa Kirin Co. Ltd. (Tokyo:4151) has acquired all ex-U.S. commercialization rights to the program, as well as a 50-50 profit share and co-development rights inside the U.S…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654313/kyowa-kirin-brings-global-reach-to-kura-s-menin-program-via-licensing-deal